Hatteras

Hatteras is a prescription oral medication that combines the statin atorvastatin with the cholesterol absorption inhibitor ezetimibe. It is formulated for the treatment of elevated cholesterol levels and is marketed in the European Union. The product contains no listed strength or dosage form in the provided data, but it is taken by mouth under medical supervision. Patients should follow their healthcare provider's guidance regarding dosage and monitoring.

Hatteras is indicated for several lipid disorders where lowering low‑density lipoprotein (LDL) cholesterol is clinically beneficial.

- Primary hypercholesterolemia, including patients with elevated LDL cholesterol despite diet. - Familial hypercholesterolemia, either heterozygous or homozygous forms, when additional LDL reduction is needed. - Mixed dyslipidemia characterized by high LDL and triglycerides with low high‑density lipoprotein (HDL). - Secondary prevention of cardiovascular events in patients with established atherosclerotic disease. - Adjunct therapy for patients who cannot achieve target lipid levels with statin monotherapy.

The safety profile of Hatteras reflects the combined actions of atorvastatin and ezetimibe, with side effects ranging from mild to rare serious events.

Common: - Muscle aches or weakness, especially during the first weeks of therapy. - Elevated liver enzymes detected in routine blood tests. - Gastrointestinal discomfort such as nausea, abdominal pain, or diarrhea. - Headache or dizziness that may resolve with continued use. - Fatigue or general weakness. - Skin rash or itching.

Serious: - Myopathy or rhabdomyolysis presenting with severe muscle pain and dark urine. - Acute liver injury indicated by jaundice, severe fatigue, or marked enzyme elevation.

Before initiating Hatteras, clinicians should assess patient history and laboratory values to minimize risk and ensure appropriate monitoring throughout treatment.

- Baseline and periodic liver function tests to detect potential hepatotoxicity. - Assessment of creatine kinase (CK) levels if muscle symptoms develop. - Caution in patients with a history of liver disease, renal impairment, or hypothyroidism. - Review all concomitant medications for possible statin or ezetimibe interactions. - Avoid use during pregnancy or lactation unless clearly indicated by a physician. - Consider dose adjustment in elderly patients or those with reduced metabolic capacity. - Counsel patients on the importance of maintaining a low‑fat diet and regular exercise.

Hatteras may interact with other drugs that affect cholesterol metabolism, liver enzymes, or muscle tissue, requiring careful review of a patient’s medication list.

Avoid: - Strong CYP3A4 inhibitors such as clarithromycin, itraconazole, or HIV protease inhibitors. - Fibrates (gemfibrozil) combined with high‑dose statins due to increased myopathy risk. - Concomitant use of cyclosporine, which can raise atorvastatin concentrations.

Use with caution: - Other lipid‑lowering agents (niacin, omega‑3 fatty acids) that may amplify side effects. - Anticoagulants like warfarin, as statins can affect INR stability. - Certain antihypertensive agents (e.g., calcium channel blockers) that may alter statin metabolism. - Herbal supplements such as St. John’s wort that induce CYP enzymes.